Monte Rosa Therapeutics

GLUE · NASDAQ

$11.36+$0.70 (+6.57%)TodayMarket closed · Oct 20, 7:47 PM ET

Prev close $10.66

GLUE analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $29.38 (+158.6% upside)

Low: $25.25
Now: $11.36
High: $38.85

Upgrades and downgrades

The latest rating actions, newest first

GLUE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 12, 2026	Initiates	Buy	$17.00 → $19.00	0%
HC Wainwright & Co.	Oct 5, 2026	Maintains	Buy	$25.00	32%
HC Wainwright & Co.	Oct 1, 2026	Initiates	Buy	$25.00	32%
Wedbush	Sep 9, 2026	Maintains	Outperform	$27.00	39%
Guggenheim	Aug 25, 2026	Maintains	Buy	$28.00	62%
JP Morgan	Aug 7, 2026	Maintains	Overweight	$31.00 → $27.00	40%
Guggenheim	Aug 7, 2026	Maintains	Buy	$35.00 → $28.00	62%
Wells Fargo	Aug 7, 2026	Maintains	Overweight	$29.00 → $27.00	54%
Wedbush	Aug 3, 2026	Maintains	Outperform	$37.00 → $27.00	39%
Guggenheim	Jun 30, 2026	Maintains	Buy	$30.00 → $35.00	62%

The case for and against

Updated Oct 15, 2026

Bull case

Monte Rosa Therapeutics is compelling because its QuEEN-enabled molecular glue platform is already producing human pharmacology across multiple programs, reducing platform risk while preserving substantial upside from diversified clinical shots on goal in inflammation and oncology. MRT-8102 has shown strong dose-dependent hsCRP suppression, 80–90% NEK7 depletion, and a clean safety profile, while MRT-2359 has generated meaningful PSA50 and radiographic responses in heavily pretreated mCRPC patients, including AR-mutant cases. In addition, the Novartis partnership on MRT-6160 has delivered $50M in milestone payment, with up to $2.1B in total milestones possible, and the company’s three collaborations plus a $345M January 2026 equity raise support a runway out to 2029.

Bear case

Monte Rosa Therapeutics is fundamentally pressured by a high-risk, low-certainty pipeline in which MRT-8102 must still prove it can outperform direct NLRP3 inhibitors that already show strong hsCRP reductions, while the company’s own comparisons are not head-to-head and do not establish clear clinical superiority. With no product revenue, reliance on collaboration funding, and cash and marketable securities declining to $626 million as of June 30, 2026 from $671.2 million at March 31, 2026, its valuation depends heavily on early programs that carry only 15% to 35% modeled approval probabilities and meaningful execution risk. Although the enterprise value is estimated at about $2.59 billion and end-3Q27 net cash at roughly $348 million, the stock’s fundamentals remain vulnerable to clinical failure, safety issues across the pipeline, competitive pressure, and potential dilution if development slows or partner economics disappoint.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.